Antibody to CMRF35-Like Molecule 2, CD300e A Novel Biomarker Detected in Patients with Fulminant Type 1 Diabetes.

Fulminant type 1 diabetes (FT1D) is a distinct subtype of type 1 diabetes and is fatal without immediate diagnosis and treatment. At present, there are no biomarkers for early and predictive detection of FT1D.First, we analyzed a total of 6 serum samples from 3 patients with FT1D (1 sample in the ac...

Full description

Bibliographic Details
Main Authors: Fumitaka Haseda, Akihisa Imagawa, Hiroyoshi Nishikawa, Shinobu Mitsui, Chiharu Tsutsumi, Reiko Fujisawa, Hiroyuki Sano, Yuko Murase-Mishiba, Jungo Terasaki, Shimon Sakaguchi, Toshiaki Hanafusa
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2016-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4981355?pdf=render
id doaj-69bc76783763486f8f395002dcf1e483
record_format Article
spelling doaj-69bc76783763486f8f395002dcf1e4832020-11-24T21:48:34ZengPublic Library of Science (PLoS)PLoS ONE1932-62032016-01-01118e016057610.1371/journal.pone.0160576Antibody to CMRF35-Like Molecule 2, CD300e A Novel Biomarker Detected in Patients with Fulminant Type 1 Diabetes.Fumitaka HasedaAkihisa ImagawaHiroyoshi NishikawaShinobu MitsuiChiharu TsutsumiReiko FujisawaHiroyuki SanoYuko Murase-MishibaJungo TerasakiShimon SakaguchiToshiaki HanafusaFulminant type 1 diabetes (FT1D) is a distinct subtype of type 1 diabetes and is fatal without immediate diagnosis and treatment. At present, there are no biomarkers for early and predictive detection of FT1D.First, we analyzed a total of 6 serum samples from 3 patients with FT1D (1 sample in the acute and 1 in the sub-acute phases from each patient) by seromic analysis. Second, titres of the antibody were measured by ELISA in sera from 30 patients with FT1D (both in the acute and sub-acute phases), 13 patients with FT1D in the chronic phase, 32 patients with autoimmune type 1 (type 1A) diabetes (T1AD), 30 patients with type 2 diabetes (T2D), 23 patients with autoimmune thyroid disease (AITD) and 31 healthy control subjects (HC).Seromic analysis revealed 9 antibodies which showed high signals from all 3 patients with FT1D in the acute phase. Among them, the titre of anti-CD300e antibody was significantly higher in FT1D patients in the acute phase than that in T1AD, T2D, AITD patients and HC, as determined by ELISA (P<0.01, respectively). The titre of anti-CD300e antibody was also higher in FT1D in the acute phase than that in the sub-acute phase (P = 0.0018, Wilcoxon signed-rank test). The titre of anti-LGALS3 antibody in FT1D patients in the acute phase did not differ from that in patients with FT1D in the sub-acute phase, T1AD, T2D, AITD and HC.The titre of a novel antibody, anti-CD300e, was high in sera from patients with FT1D. This antibody might be a diagnostic marker and provide new insight into the pathogenesis of FT1D.http://europepmc.org/articles/PMC4981355?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Fumitaka Haseda
Akihisa Imagawa
Hiroyoshi Nishikawa
Shinobu Mitsui
Chiharu Tsutsumi
Reiko Fujisawa
Hiroyuki Sano
Yuko Murase-Mishiba
Jungo Terasaki
Shimon Sakaguchi
Toshiaki Hanafusa
spellingShingle Fumitaka Haseda
Akihisa Imagawa
Hiroyoshi Nishikawa
Shinobu Mitsui
Chiharu Tsutsumi
Reiko Fujisawa
Hiroyuki Sano
Yuko Murase-Mishiba
Jungo Terasaki
Shimon Sakaguchi
Toshiaki Hanafusa
Antibody to CMRF35-Like Molecule 2, CD300e A Novel Biomarker Detected in Patients with Fulminant Type 1 Diabetes.
PLoS ONE
author_facet Fumitaka Haseda
Akihisa Imagawa
Hiroyoshi Nishikawa
Shinobu Mitsui
Chiharu Tsutsumi
Reiko Fujisawa
Hiroyuki Sano
Yuko Murase-Mishiba
Jungo Terasaki
Shimon Sakaguchi
Toshiaki Hanafusa
author_sort Fumitaka Haseda
title Antibody to CMRF35-Like Molecule 2, CD300e A Novel Biomarker Detected in Patients with Fulminant Type 1 Diabetes.
title_short Antibody to CMRF35-Like Molecule 2, CD300e A Novel Biomarker Detected in Patients with Fulminant Type 1 Diabetes.
title_full Antibody to CMRF35-Like Molecule 2, CD300e A Novel Biomarker Detected in Patients with Fulminant Type 1 Diabetes.
title_fullStr Antibody to CMRF35-Like Molecule 2, CD300e A Novel Biomarker Detected in Patients with Fulminant Type 1 Diabetes.
title_full_unstemmed Antibody to CMRF35-Like Molecule 2, CD300e A Novel Biomarker Detected in Patients with Fulminant Type 1 Diabetes.
title_sort antibody to cmrf35-like molecule 2, cd300e a novel biomarker detected in patients with fulminant type 1 diabetes.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2016-01-01
description Fulminant type 1 diabetes (FT1D) is a distinct subtype of type 1 diabetes and is fatal without immediate diagnosis and treatment. At present, there are no biomarkers for early and predictive detection of FT1D.First, we analyzed a total of 6 serum samples from 3 patients with FT1D (1 sample in the acute and 1 in the sub-acute phases from each patient) by seromic analysis. Second, titres of the antibody were measured by ELISA in sera from 30 patients with FT1D (both in the acute and sub-acute phases), 13 patients with FT1D in the chronic phase, 32 patients with autoimmune type 1 (type 1A) diabetes (T1AD), 30 patients with type 2 diabetes (T2D), 23 patients with autoimmune thyroid disease (AITD) and 31 healthy control subjects (HC).Seromic analysis revealed 9 antibodies which showed high signals from all 3 patients with FT1D in the acute phase. Among them, the titre of anti-CD300e antibody was significantly higher in FT1D patients in the acute phase than that in T1AD, T2D, AITD patients and HC, as determined by ELISA (P<0.01, respectively). The titre of anti-CD300e antibody was also higher in FT1D in the acute phase than that in the sub-acute phase (P = 0.0018, Wilcoxon signed-rank test). The titre of anti-LGALS3 antibody in FT1D patients in the acute phase did not differ from that in patients with FT1D in the sub-acute phase, T1AD, T2D, AITD and HC.The titre of a novel antibody, anti-CD300e, was high in sera from patients with FT1D. This antibody might be a diagnostic marker and provide new insight into the pathogenesis of FT1D.
url http://europepmc.org/articles/PMC4981355?pdf=render
work_keys_str_mv AT fumitakahaseda antibodytocmrf35likemolecule2cd300eanovelbiomarkerdetectedinpatientswithfulminanttype1diabetes
AT akihisaimagawa antibodytocmrf35likemolecule2cd300eanovelbiomarkerdetectedinpatientswithfulminanttype1diabetes
AT hiroyoshinishikawa antibodytocmrf35likemolecule2cd300eanovelbiomarkerdetectedinpatientswithfulminanttype1diabetes
AT shinobumitsui antibodytocmrf35likemolecule2cd300eanovelbiomarkerdetectedinpatientswithfulminanttype1diabetes
AT chiharutsutsumi antibodytocmrf35likemolecule2cd300eanovelbiomarkerdetectedinpatientswithfulminanttype1diabetes
AT reikofujisawa antibodytocmrf35likemolecule2cd300eanovelbiomarkerdetectedinpatientswithfulminanttype1diabetes
AT hiroyukisano antibodytocmrf35likemolecule2cd300eanovelbiomarkerdetectedinpatientswithfulminanttype1diabetes
AT yukomurasemishiba antibodytocmrf35likemolecule2cd300eanovelbiomarkerdetectedinpatientswithfulminanttype1diabetes
AT jungoterasaki antibodytocmrf35likemolecule2cd300eanovelbiomarkerdetectedinpatientswithfulminanttype1diabetes
AT shimonsakaguchi antibodytocmrf35likemolecule2cd300eanovelbiomarkerdetectedinpatientswithfulminanttype1diabetes
AT toshiakihanafusa antibodytocmrf35likemolecule2cd300eanovelbiomarkerdetectedinpatientswithfulminanttype1diabetes
_version_ 1725891473605394432